Showing 5121-5130 of 8160 results for "".
- FDA Cracks Down on Sonar For Distributing Unapproved Derm Drugshttps://practicaldermatology.com/news/fda-cracks-down-on-sonar-for-distributing-unapproved-derm-drugs/2458153/U.S. District Judge Kathleen M. Williams for the Southern District of Florida entered a consent decree of permanent injunction between the United States and Stratus Pharmaceuticals Inc. of Miami, Florida, Sonar Products Inc. of Carlstadt, New Jersey an
- PsA Patients Failing Anti-TNF Drugs May Do Well on Taltzhttps://practicaldermatology.com/news/psa-patients-who-fail-anti-tnf-drugs-may-do-well-on-taltz/2458154/New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated. Eli Lilly has filed a supple
- Leo Pharma Vet Named New COO for DermaRitehttps://practicaldermatology.com/news/leo-pharma-vet-named-new-coo-for-dermarite/2458157/Barbara J. Osborne is DermaRite Industries’s new Chief Commercial Officer. In her role, Ms. Osborne will be responsible for driving the company's sales and commercialization efforts. She recently served as the U.S. Division President
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull
- May 26, 2017 is Don't Fry Dayhttps://practicaldermatology.com/news/may-26-2017-is-dont-fry-day/2458173/The Friday before Memorial Day (May 26, 2017) is Don’t Fry Day. The day, designated by the American Society for Dermatologic Surgery Association (ASDSA) in collaboration with
- Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clueshttps://practicaldermatology.com/news/largest-psoriasis-meta-analysis-to-date-yields-new-genetic-clues/2458176/A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how — and why — psoriasis develops. University of Michigan researchers, working with partners across the globe, published the work in
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- DerMend's New Line Takes On Mature Skin Issueshttps://practicaldermatology.com/news/dermends-new-line-takes-on-mature-skin-issues/2458190/DerMend® is launching DerMend® Mature Skin Solutions. The new product line features DerMend®Fragile Skin Moisturizing Formula, DerMend® Moisturizing Anti-Itch Lotion and DerMend® Moisturizing Bruise Formu
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re